By Mill Chart
Last update: Nov 27, 2023
Consider AMGEN INC (NASDAQ:AMGN) as a top pick for dividend investors, identified by our stock screening tool. NASDAQ:AMGN shines in terms of profitability, solvency, and liquidity, all while paying a decent dividend. Let's dive deeper into the analysis.
To gauge a stock's dividend quality, ChartMill utilizes a Dividend Rating ranging from 0 to 10. This comprehensive assessment considers various dividend aspects, including yield, history, growth, and sustainability. NASDAQ:AMGN has achieved a 7 out of 10:
Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:AMGN has achieved a 5 out of 10:
ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:AMGN, the assigned 8 is noteworthy for profitability:
Our Best Dividend screener lists more Best Dividend stocks and is updated daily.
Check the latest full fundamental report of AMGN for a complete fundamental analysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
NASDAQ:AMGN (2/23/2024, 10:48:02 AM)
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.
Regeneron (REGN) and Vertex Pharmaceuticals (VRTX) join the $100B market cap club in the biotech industry, outperforming their rivals last year. Read more here.
/PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth...
Has Amgen been a market-beating stock?
Novartis (NVS) is jumping on the weight-loss bandwagon, aiming to develop next-generation anti-obesity drugs that could potentially address some of the drawback
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.
Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive.
Investors interested in a steadily rising stream of passive income will find what they're looking for with these dividend payers.
It faces both clinical and competitive barriers, but they might not matter.